Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
‘NDA Is Winning Around 100 Of 121 Seats’, Claims Bihar Deputy CM Samrat Choudhary After First Phase Of Voting Concludes - VIDEO
Thane News: Bhiwandi Nizampur Municipal Corporation Announces 100% Interest Waiver On Property Tax Arrears; ₹200 Crore Recovery Target
Bihar Elections 2025: EVMs Sealed By Polling Officials As Voting For First Phase Concludes - VIDEO
Karnataka High Court Refuses To Vacate Stay On Govt Order Restricting RSS Activities
